Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

WuXi PharmaTech VC Fund Participates in Syros Pharma's Initial Round

publication date: Apr 22, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Syros Pharmaceuticals, a Boston area startup, raised $30 million to develop treatments for cancer and other diseases by controlling the switches that regulate gene expression. The WuXi PharmaTech Corporate Venture Fund participated in the funding, which was led by ARCH Venture Partners and Flagship Ventures. More details....

Stock Symbol: (NYSE: WX)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors